Glucagon-like peptide 1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are very interesting in this respect since many preclinical studies have shown their positive effects on stroke recovery [37, 39, 54]. This evidence concerns the gene DPP4 and stroke disorder.